| PRECLINICAL | evidence | Various GLP-1 Receptor Agonist Preference Use with a Special Focus on Oral and Subcutaneous Forms in Poland. | Tirzepatide | — | 2025-11-12 |
| PRECLINICAL | evidence | Letter by Zhao et al Regarding Article, "Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity". | Tirzepatide | — | 2025-11-11 |
| PRECLINICAL | evidence | [The perspectives in obesity and type 2 diabetes therapy: the present and future of incretin therapy]. | Tirzepatide | Glycemic control | 2025-11-11 |
| PRECLINICAL | evidence | Response by Zile et al to Letter Regarding Article, "Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity". | Tirzepatide | — | 2025-11-11 |
| PRECLINICAL | evidence | Current and Emerging Roles of GLP1 Receptor Agonists Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure. | Tirzepatide | — | 2025-11-10 |
| PRECLINICAL | evidence | Cardiovascular Therapeutics at the Crossroads: Pharmacological, Genetic, and Digital Frontiers. | Tirzepatide | — | 2025-11-10 |
| PRECLINICAL | evidence | Glucagon-like peptide 1 receptor agonists and the clinical outcomes of inflammatory bowel disease: a systematic review and meta-analysis. | Tirzepatide | Weight & fat loss | 2025-11-08 |
| PRECLINICAL | evidence | Trump strikes deal with Ozempic and Mounjaro makers to cut prices of obesity injections. | Mounjaro | — | 2025-11-07 |
| PRECLINICAL | evidence | Semaglutide and Tirzepatide Prescribing for Obesity in Patients With Preexisting Comorbid Cancers. | Tirzepatide | — | 2025-11-06 |
| PRECLINICAL | evidence | Exploring the Evidence for Personalized Pharmacotherapy in Type 2 Diabetes-A Systematic Review. | Tirzepatide | — | 2025-11-06 |
| PRECLINICAL | evidence | Tirzepatide for fertility-sparing treatment in obese/overweight patients with endometrial cancer and atypical hyperplasia: a phase II single-arm clinical trial protocol. | Tirzepatide | Weight & fat loss | 2025-11-05 |
| PRECLINICAL | evidence | Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review. | Tirzepatide | Weight & fat loss | 2025-11-05 |
| PRECLINICAL | evidence | Tirzepatide as a Potential Disease-Modifying Therapy in Lipedema: A Narrative Review on Bridging Metabolism, Inflammation, and Fibrosis. | Tirzepatide | — | 2025-11-05 |
| PRECLINICAL | evidence | Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials. | Tirzepatide | — | 2025-11-04 |
| PRECLINICAL | evidence | Efficacy and Safety of Tirzepatide in Refractory Hypoglycemia Associated with Esophagojejunostomy. | Tirzepatide | — | 2025-11-01 |
| PRECLINICAL | evidence | Redefining Cystic Fibrosis-Related Diabetes Management With Tirzepatide: A Case Report. | Tirzepatide | — | 2025-11-01 |
| PRECLINICAL | evidence | Real-World Weight Loss Observed With Semaglutide and Tirzepatide in Patients with Overweight or Obesity and Without Type 2 Diabetes (SHAPE). | Mounjaro | Weight & fat loss | 2025-11-01 |
| PRECLINICAL | evidence | Evaluation of the Short-Term Effect of Tirzepatide on Liver Fibrosis Biomarkers Stratified by the Fibrosis-3 Index (FIB-3) in Patients With Type 2 Diabetes Mellitus. | Tirzepatide | — | 2025-11-01 |
| PRECLINICAL | evidence | An Online Prescription for Hospitalisation: Euglycaemic Ketoacidosis Caused by an Online Tirzepatide Prescription. | Mounjaro | — | 2025-11-01 |
| PRECLINICAL | evidence | Prospecting the use of tirzepatide in combating obesity in Pakistan. | Tirzepatide | — | 2025-11-01 |
| PRECLINICAL | evidence | Acute Mesenteric Ischemia as a Severe Complication Associated With Tirzepatide: A Case Report and Safety Alert. | Tirzepatide | — | 2025-11-01 |
| PRECLINICAL | evidence | Pancreatitis in Patients Receiving Tirzepatide (Mounjaro): A One-Year Audit in a UK District General Hospital. | Mounjaro | — | 2025-11-01 |
| PRECLINICAL | evidence | Advances of pharmacological therapies in lipodystrophy syndromes: current evidence and future directions. | Tirzepatide | Weight & fat loss | 2025-11-01 |
| PRECLINICAL | evidence | Diverticular Stricture and Hepatic Abscess Formation During Tirzepatide Therapy for Obesity. | Tirzepatide | — | 2025-11-01 |
| PRECLINICAL | evidence | Medical Management of Obesity: A Comprehensive Review of Food and Drug Administration (FDA)-Approved and Investigational Therapies. | Tirzepatide | — | 2025-11-01 |
| PRECLINICAL | evidence | Association Between Semaglutide or Tirzepatide Therapy and Residual Gastric Content: A Potential Danger During Upper Endoscopy. | Tirzepatide | — | 2025-11-01 |
| PRECLINICAL | evidence | The Obesity Drug Revolution: New Frontiers in Pharmacotherapy. | Tirzepatide | — | 2025-11-01 |
| PRECLINICAL | evidence | Cardiovascular Health in the Shadow of Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: An Emerging Paradigm. | Tirzepatide | — | 2025-11-01 |
| PRECLINICAL | evidence | Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis. | Tirzepatide | — | 2025-11-01 |
| PRECLINICAL | evidence | [In obese, non-diabetic adults, tirzepatide results in greater weight loss than semaglutide.]. | Tirzepatide | — | 2025-11-01 |
| PRECLINICAL | evidence | The Thyroid Twist: How GLP-1 Agonists Are Influencing Autoimmune Thyroid Care. | Tirzepatide | — | 2025-11-01 |
| PRECLINICAL | evidence | Oral Delivery of Semaglutide and Tirzepatide Using Milk-Derived Small Extracellular Vesicles. | Tirzepatide | — | 2025-11-01 |
| PRECLINICAL | evidence | Tirzepatide for weight loss. | Tirzepatide | — | 2025-11-01 |
| PRECLINICAL | evidence | Comparative Efficacy of Tirzepatide vs Semaglutide on Liver and Cardiovascular Related Outcomes in Patients with MASLD/MASH, Obesity, and Type 2 Diabetes Mellitus: A Real-World Cohort Study. | Tirzepatide | — | 2025-11-01 |
| PRECLINICAL | evidence | New drugs for weight loss: Why change in body composition matters and why nutrition and exercise remain paramount. | Tirzepatide | Weight & fat loss | 2025-11-01 |
| PRECLINICAL | evidence | [Not Available]. | Tirzepatide | — | 2025-11-01 |
| PRECLINICAL | evidence | Tirzepatide and the NHS: are we creating a two-tier obesity treatment system? | Tirzepatide | — | 2025-11-01 |
| PRECLINICAL | evidence | Effect of sleep apnoea interventions on multiple health outcomes: an umbrella review of meta-analyses of randomised controlled trials. | Tirzepatide | — | 2025-11-01 |
| PRECLINICAL | evidence | Methodological considerations in tirzepatide-bariatric surgery comparative study. | Tirzepatide | — | 2025-11-01 |
| PRECLINICAL | evidence | Real-World Effectiveness of Tirzepatide versus Semaglutide on HbA1c and Weight in Patients with Type 2 Diabetes. | Mounjaro | — | 2025-11-01 |
| PRECLINICAL | evidence | Intractable Vomiting in the Setting of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist and Cannabis Usage. | Tirzepatide | — | 2025-11-01 |
| PRECLINICAL | evidence | Zepbound: A novel pharmacological approach to Obstructive Sleep Apnoea management. | Zepbound | — | 2025-11-01 |
| PRECLINICAL | evidence | Tirzepatide, a dual GLP-1 and GIP receptor agonist, promotes bone loss in obese mice via gut microbial-related metabolites. | Tirzepatide | — | 2025-11-01 |
| PRECLINICAL | evidence | Protein-Ligand Interactions in Cardiometabolic Drug Targets: Focus on Weight Loss and Cardioprotection. | Tirzepatide | — | 2025-10-30 |
| PRECLINICAL | evidence | Tirzepatide for adults living with obesity. | Tirzepatide | Weight & fat loss | 2025-10-30 |
| PRECLINICAL | evidence | Comparative Renal Safety of Tirzepatide and Semaglutide: An FDA Adverse Event Reporting System (FAERS)-Disproportionality Study. | Tirzepatide | — | 2025-10-29 |
| PRECLINICAL | evidence | Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 European Society of Cardiology Conference. | Tirzepatide | Lipid & cardiovascular markers | 2025-10-28 |
| PRECLINICAL | evidence | Tirzepatide-induced weight loss and obstructive sleep apnea improvement in an adult with type 2 diabetes: A case report. | Tirzepatide | Sleep quality · n = 1 | 2025-10-24 |
| PRECLINICAL | evidence | Tirzepatide protects the heart from doxorubicin-induced cardiotoxicity by modulating endoplasmic reticulum (ER) stress and HMGCoA reductase 1 expression. | Tirzepatide | — | 2025-10-24 |
| PRECLINICAL | evidence | Tirzepatide vs. Semaglutide for Obesity Treatment. Reply. | Tirzepatide | — | 2025-10-23 |